EUVIMEDEUVIMED entdecken
Crossref

TNF-α and IL-1β Antibodies Alongside Exogenous IL-10 Treatment Ameliorates DSS-Induced Colitis by Modulating the Apoptosis-Autophagy Pathways in Splenic Macrophages

Biswadev Bishayi, Gopinath Mukherjee, Shakhi Ghosh, Anindita Gope

Journal of Clinical Immunology & Microbiology · 2026

DOI: 10.46889/jcim.2026.7304 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Immunology & Microbiology, 2026. Verfasst von Biswadev Bishayi und 3 weiteren Autor:innen. Die Arbeit nennt 67 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Inflammatory Bowel Disease (IBD) such as colitis is a debilitating condition driven by a complex interplay of immune dysregulation, oxidative stress and cellular damage. Pro-inflammatory cytokines like TNF-α and IL-1β are central mediators of this pathology. This study aimed to investigate the therapeutic efficacy through dual neutralization of TNF-α and IL-1β, supplemented with IL-10 in a DSS-induced colitis. Colitis was induced by Dextran Sodium Sulphate (DSS) in drinking water for 7 days in mice and a treatment group received pre-treatment with antibodies against Tumor Necrosis Factor Alpha (TNF-α) and Interleukins (IL-1β) followed by post-treatment with IL-10. DSS challenged mice, exhibited pronounced splenic macrophage activation, elevated ROS production and heightened lipid peroxidation. Cells of DSS-administered mice also exhibited a significant pro-inflammatory state, elevated NF-κB, severe oxidative stress, upregulation of apoptosis markers. Macrophages of dual treated mice along with IL-10 showed a significant restoration of the antioxidant defence system. Furthermore, protein expression of autophagy-related proteins Beclin-1, LC3-II in the macrophages of treated group, indicating a normalization of cellular homeostasis. Our findings demonstrate that this multi-targeted therapy effectively mitigates colitis by suppressing inflammation, oxidative burden and restoring cellular degradation pathways in macrophages. These findings suggest that the dual neutralization of TNF-α/IL-1β may be chosen as an alternative, highly effective therapeutic approach for controlling colitis.

Zitieren

APA

Bishayi, B., Mukherjee, G., Ghosh, S., & Gope, A. (2026). TNF-α and IL-1β Antibodies Alongside Exogenous IL-10 Treatment Ameliorates DSS-Induced Colitis by Modulating the Apoptosis-Autophagy Pathways in Splenic Macrophages. Journal of Clinical Immunology & Microbiology. https://doi.org/10.46889/jcim.2026.7304

Vancouver

Bishayi B, Mukherjee G, Ghosh S, Gope A. TNF-α and IL-1β Antibodies Alongside Exogenous IL-10 Treatment Ameliorates DSS-Induced Colitis by Modulating the Apoptosis-Autophagy Pathways in Splenic Macrophages. Journal of Clinical Immunology & Microbiology. 2026. doi:10.46889/jcim.2026.7304

BibTeX
@article{Bishayi2026,
  author = {Bishayi, Biswadev and Mukherjee, Gopinath and Ghosh, Shakhi and Gope, Anindita},
  title = {TNF-α and IL-1β Antibodies Alongside Exogenous IL-10 Treatment Ameliorates DSS-Induced Colitis by Modulating the Apoptosis-Autophagy Pathways in Splenic Macrophages},
  journal = {Journal of Clinical Immunology & Microbiology},
  year = {2026},
  doi = {10.46889/jcim.2026.7304}
}
Kostenlos starten →